In recent years, the microenvironment-targeted treatment of GC has begun to rise, including using various new drugs targeting FGFR [47], VEGFR [48, 49], MMP9 [50] and TGF-β1 [51] for reshaping the matrix microenvironment [52]. This evidence concerns the gene MMP9 and gastric cancer.